Myocardial infarction and individual nonsteroidal anti‐inflammatory drugs meta‐analysis of observational studies
ConclusionsMost frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses. Copyright © 2013 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - April 25, 2013 Category: Drugs & Pharmacology Authors: Cristina Varas‐Lorenzo, Nuria Riera‐Guardia, Brian Calingaert, Jordi Castellsague, Francesco Salvo, Federica Nicotra, Miriam Sturkenboom, Susana Perez‐Gutthann Tags: Review Source Type: research
Synthesis, Cytotoxicity, and Pro‐Apoptosis Activity of Etodolac Hydrazide Derivatives as Anticancer Agents
Abstract
Etodolac hydrazide and a novel series of etodolac hydrazide‐hydrazones 3–15 and etodolac 4‐thiazolidinones 16–26 were synthesized in this study. The structures of the new compounds were determined by spectral (FT‐IR, 1H NMR, 13C NMR, HREI‐MS) methods. Some selected compounds were determined at one dose toward the full panel of 60 human cancer cell lines by the National Cancer Institute (NCI, Bethesda, USA). 2‐(1,8‐Diethyl‐1,3,4,9‐tetrahydropyrano[3,4‐b]indole‐1‐yl)acetic acid[(4‐chlorophenyl)methylene]hydrazide 9 demonstrated the most marked effect on the prostate cancer cell line PC‐...
Source: Archiv der Pharmazie - April 22, 2013 Category: Drugs & Pharmacology Authors: Pelin Çıkla, Derya Özsavcı, Özlem Bingöl‐Özakpınar, Azize Şener, Özge Çevik, Suna Özbaş‐Turan, Jülide Akbuğa, Fikrettin Şahin, Ş. Güniz Küçükgüzel Tags: Full Paper Source Type: research
Sucrose Stearate-Enriched Lipid Matrix Tablets of Etodolac: Modulation of Drug Release, Diffusional Modeling and Structure Elucidation Studies.
Abstract
Etodolac is a non-steroidal anti-inflammatory drug having an elimination half-life of 7 h; oral doses are given every 6-8 h. The aim of current work was the development of controlled-release etodolac lipid matrix tablets. The variables influencing design of these tablets (L1-L28) by the hot fusion method were investigated including; (1) lipid type (stearic acid, cetyl alcohol, cetostearyl alcohol, Imwitor® 900K, Precirol® ATO 5 and Compritol® ATO 888), (2) drug/lipid ratio (1:0.25 and 1:0.50, respectively), (3) filler type (lactose, Avicel® PH101 and their physical mixtures; 2:1, 1:1, and 1:...
Source: AAPS PharmSciTech - April 10, 2013 Category: Drugs & Pharmacology Authors: Abd-Elbary A, Tadros MI, Alaa-Eldin AA Tags: AAPS PharmSciTech Source Type: research
First multifocal bullous fixed drug eruption due to etodolac.
PMID: 23453256 [PubMed - as supplied by publisher] (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - February 27, 2013 Category: Allergy & Immunology Authors: Koca Kalkan I, Kalpaklioglu AF, Atasoy P, Karabulut AA Tags: Allergol Immunopathol (Madr) Source Type: research
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling
In this study, we observed that celecoxib treatment at clinically relevant concentrations induced epithelial-mesenchymal transition (EMT) in NSCLC cells regardless of Cox-2 status, which, however, was not recapitulated using another Cox-2 inhibitor, etodolac. Celecoxib-stimulated EMT in turn promoted cell invasion and rendered cells resistant to chemotherapy. Further mechanistic investigation by disrupting the integrity of signaling pathways using specific inhibitors or RNA interference revealed that celecoxib-induced EMT in NSCLC cells is indispensable of transforming growth factor-β1/Smad signaling. Instead, the act...
Source: Carcinogenesis - February 25, 2013 Category: Cancer & Oncology Authors: Wang, Z.-l., Fan, Z.-q., Jiang, H.-d., Qu, J.-m. Tags: Original Manuscript Source Type: research
Renal effects of carprofen and etodolac in dogs
Non-steroidal anti-inflammatory drugs (NSAIDs) have potential adverse effects on the gastrointestinal tract and kidneys. The adverse effects on the gastrointestinal tract may be reduced via administration of NSAIDs that preferentially inhibit cyclo-oxygenase (COX)-2. The effects of such drugs on renal function in dogs are not known. Adverse effects in the gastrointestinal tract and kidneys may often develop as a synergism among factors. For example, vomiting associated with NSAID-induced effects in the gastrointestinal tract can cause volume depletion and metabolic alkalosis, which can increase toxic effects of such drugs ...
Source: Advances in Small Animal Medicine and Surgery - February 1, 2013 Category: Veterinary Research Tags: Nephrology/Urology Source Type: research
